NovaBay Pharmaceuticals (NYSE:NBY) Coverage Initiated by Analysts at StockNews.com

Analysts at StockNews.com began coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY) in a note issued to investors on Sunday. The brokerage set a “hold” rating on the stock.

Separately, Ascendiant Capital Markets cut their price objective on shares of NovaBay Pharmaceuticals from $8.00 to $0.85 and set a “buy” rating for the company in a report on Monday, November 11th.

NovaBay Pharmaceuticals Stock Up 8.3 %

Shares of NYSE NBY opened at $0.76 on Friday. The firm has a 50-day simple moving average of $0.62 and a 200-day simple moving average of $0.81. The stock has a market capitalization of $3.71 million, a price-to-earnings ratio of -0.01 and a beta of 0.65. NovaBay Pharmaceuticals has a 52 week low of $0.36 and a 52 week high of $9.08.

NovaBay Pharmaceuticals Company Profile

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.